z-logo
open-access-imgOpen Access
Amphotericin B and Itraconazole for Treatment of DisseminatedPenicillium marneffeiInfection in Human Immunodeficiency Virus–Infected Patients
Author(s) -
Thira Sirisanthana,
Khuanchai Supparatpinyo,
Joseph H. Perriëns,
Kenrad E. Nelson
Publication year - 1998
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/520280
Subject(s) - penicillium marneffei , amphotericin b , itraconazole , medicine , adverse effect , opportunistic infection , mycosis , regimen , sida , aids related opportunistic infections , virology , human immunodeficiency virus (hiv) , immunology , microbiology and biotechnology , viral disease , dermatology , antifungal , biology , coinfection
Disseminated infection with Penicillium marneffei is common in patients infected with human immunodeficiency virus (HIV) in Southeast Asia. Treatment with amphotericin B alone is effective but requires a prolonged hospital stay. We conducted an open-label nonrandomized study to evaluate the efficacy and safety of treatment with amphotericin B at a dosage of 0.6 mg/(kg.d) intraveneously for 2 weeks, followed by a 400-mg/d dosage of oral itraconazole for 10 weeks. Of the 74 HIV-infected patients we studied who had disseminated P. marneffei infection, diagnosed by positive fungal culture and clinical evidence of infection, 72 (97.3%) responded to the treatment. There were no serious adverse drug effects. It was concluded that the regimen was effective and safe for treatment of disseminated P. marneffei infection in HIV-infected patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom